0000000000757486

AUTHOR

Uwe Pichlmeier

showing 2 related works from this author

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with ac…

2019

Background: Further improvement of preparative regimens before allogeneic haemopoietic stem cell transplantation (HSCT) is an unmet medical need for the growing number of older or comorbid patients with acute myeloid leukaemia or myelodysplastic syndrome. We aimed to evaluate the efficacy and safety of conditioning with treosulfan plus fludarabine compared with reduced-intensity busulfan plus fludarabine in this population. Methods: We did an open-label, randomised, non-inferiority, phase 3 trial in 31 transplantation centres in France, Germany, Hungary, Italy, and Poland. Eligible patients were 18–70 years, had acute myeloid leukaemia in first or consecutive complete haematological remissi…

AdultMalemedicine.medical_specialtyTransplantation ConditioningPopulationMedizinAntineoplastic AgentsTreosulfanDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumanseducationBusulfanPreparative RegimenAgededucation.field_of_studybusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedInterim analysis3. Good healthFludarabineTransplantationRegimenLeukemia Myeloid Acute030220 oncology & carcinogenesisMyelodysplastic SyndromesFemalebusinessBusulfanVidarabine030215 immunologymedicine.drug
researchProduct

Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with acute lymphoblastic leukemi…

2014

Abstract Total-body-irradiation (TBI) based preparative regimens are considered as standard conditioning therapy for allogeneic stem cell transplantation (AHSC) in patients with acute lymphoblastic leukemia (ALL). Within a multi-center prospective phase II study we have investigated the toxicity and efficacy of a non-TBI-based regimen consisting of treosulfan, etoposide, and cyclophosphamide in patients with ALL. Inclusion criteria were complete remission, non-eligibility for TBI or patient’s wish to avoid TBI. Between July 2007 and August 2010, 50 patients with a median age of 46.5 years were enrolled at ten German centers. 74% of the patients were in 1. CR and 26% 2. or higher CR.The cond…

medicine.medical_specialtyCyclophosphamidebusiness.industrymedicine.medical_treatmentImmunologyPhases of clinical researchCell BiologyHematologyHematopoietic stem cell transplantationTreosulfanBiochemistrySurgeryTransplantationRegimenInternal medicinemedicineCumulative incidencebusinessEtoposidemedicine.drug
researchProduct